Are Estring® and Vagifem® Equally Effective and Safe for the Treatment of Urogenital Atrophy in Breast Cancer Patients on Aromatase Inhibitor Therapy?

2012 ◽  
Vol 24 (8) ◽  
pp. e128-e129 ◽  
Author(s):  
C.E. Simmons ◽  
I. Kuchuk ◽  
O.C. Freedman ◽  
T. Colgan ◽  
A. Dodd ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Aromatase Inhibitor ◽  
Cancer Patients ◽  
Inhibitor Therapy ◽  
Breast Cancer Patients ◽  
Aromatase Inhibitor Therapy ◽  
Urogenital Atrophy

FLT-PET (Fluorothymidine) and Ki-67 to measure effects of a short course of aromatase inhibitor therapy in ER+ breast cancer patients.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e22161-e22161
Author(s):  
Hannah M. Linden ◽  
Lanell Peterson ◽  
Brenda F. Kurland ◽  
Alena Novakova ◽  
Andrew Shields ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Aromatase Inhibitor ◽  
Cancer Patients ◽  
Inhibitor Therapy ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
Aromatase Inhibitor Therapy ◽  
Flt Pet ◽  
Short Course

Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy

2011 ◽  
Vol 130 (2) ◽  
pp. 569-577 ◽  
Author(s):  
Lisa Gallicchio ◽  
Ryan MacDonald ◽  
Bethany Wood ◽  
Errol Rushovich ◽  
Kathy J. Helzlsouer
Keyword(s):  
Breast Cancer ◽  
Aromatase Inhibitor ◽  
Cancer Patients ◽  
Inhibitor Therapy ◽  
Musculoskeletal Symptoms ◽  
Breast Cancer Patients ◽  
Aromatase Inhibitor Therapy
Sign in / Sign up

Export Citation Format

Share Document